Spectroscopic Quantification of Surfactants in Solid Lipid Nanoparticles
- 65 Downloads
Solid lipid nanoparticles (SLN) mainly consist of lipids and surfactants. However, the toxicity of surfactant cannot be ignored, as the surfactant may cause unexpected side effect. This study established model SLN with different surfactants, Tween 80 (T80) and poloxamer 188 (P188). It was aimed to establish ultraviolet-visible (UV-Vis) spectroscopy methods for quantifying the contents of T80 and P188 in the model SLN.
The model SLN were produced by emulsification-precipitation method, and their particle size distribution was analyzed. The calibration curves for the contents of T80 and P188 were established. Surfactants in the model SLN were extracted by ultrasonication, and UV-Vis spectroscopy methods were utilized for quantification of surfactants in SLN.
The deviation of precision and accuracy in P188 and T80 assay were acceptable, which indicated the method could be employed in sample quantification. Ten minutes was considered as the optimal ultrasonication time. And the contents of P188 and T80 were successfully measured by the established UV-Vis methods.
The UV-Vis spectroscopy methods were developed for the quantification of T80 and P188 in the model SLN. It is expected that the methods could be extended to more SLN systems and applied for the quantification of other surfactants.
KeywordsSolid lipid nanoparticles Surfactant Ultraviolet-visible Quantification Quality control
The authors would like to appreciate Mr. Yinan Pan and Mr. Jiaye Li from School of Pharmaceutical Sciences, Sun Yat-sen University for their voluntary assistant in the experiments.
Z. Huang designed the study, analyzed the data, and wrote the manuscript. M. Wu and C. Ma performed the experiments and prepared the artworks. X. Bai revised the manuscript and assisted in the data interpretation. X. Zhang and Z. Zhao revised and proof-read the manuscript. Y. Huang participated in experimental design and data analysis. X. Pan and C. Wu supervised the study and polished and proof-read the manuscript.
This work received financial support from National Science Foundation of China (No. 81673375 and 81703431), 111 project (No. B16047), and Sun Yat-sen University (No. 16ykpy23).
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflicts of interest.
- 1.Wu X, Chen HM, Wu CX, Wang JL, Zhang S, Gao J, et al. Inhibition of intrinsic coagulation improves safety and tumor-targeted drug delivery of cationic solid lipid nanoparticles. Biomaterials. 2018;156:77–87. https://doi.org/10.1016/j.biomaterials.2017.11.0110. CrossRefPubMedGoogle Scholar
- 2.Ding Y, Nielsen KA, Nielsen BP, Boje NW, Muller RH, Pyo SM. Lipid-drug-conjugate (LDC) solid lipid nanoparticles (SLN) for the delivery of nicotine to the oral cavity - optimization of nicotine loading efficiency. Eur J Pharm Biopharm. 2018;128:10–7. https://doi.org/10.1016/j.ejpb.2018.03.004.CrossRefPubMedGoogle Scholar
- 3.Rosiere R, Van Woensel M, Gelbcke M, Mathieu V, Hecq J, Mathivet T, et al. New folate-grafted chitosan derivative to improve delivery of paclitaxel-loaded solid lipid nanoparticles for lung tumor therapy by inhalation. Mol Pharm. 2018;15(3):899–910. https://doi.org/10.1021/acs.molpharmaceut.7b00846.CrossRefPubMedGoogle Scholar
- 5.Jannin V, Blas L, Chevrier S, Miolane C, Demarne F, Spitzer D. Evaluation of the digestibility of solid lipid nanoparticles of glyceryl dibehenate produced by two techniques: Ultrasonication and spray-flash evaporation. Eur J Pharm Sci. 2018;111:91–5. https://doi.org/10.1016/j.ejps.2017.09.049.CrossRefPubMedGoogle Scholar
- 6.Pereira I, Zielińska A, Ferreira NR, Silva AM, Souto EB. Optimization of linalool-loaded solid lipid nanoparticles using experimental factorial design and long-term stability studies with a new centrifugal sedimentation method. Int J Pharm. 2018;549(1):261–70. https://doi.org/10.1016/j.ijpharm.2018.07.068.CrossRefPubMedGoogle Scholar
- 7.Rigon RB, Gonçalez ML, Severino P, Alves DA, Santana MHA, Souto EB, et al. Solid lipid nanoparticles optimized by 22 factorial design for skin administration: cytotoxicity in NIH3T3 fibroblasts. Colloids Surf B: Biointerfaces. 2018;171:501–5. https://doi.org/10.1016/j.colsurfb.2018.07.065.CrossRefPubMedGoogle Scholar
- 13.Arechabala B, Coiffard C, Rivalland P, Coiffard LJM, de Roeck-Holtzhauer Y. Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release. J Appl Toxicol. 1999;19(3):163–5. https://doi.org/10.1002/(Sici)1099-1263(199905/06)19:3<163::Aid-Jat561>3.0.Co;2-H.CrossRefPubMedGoogle Scholar
- 15.Singh-Joy SD, McLain VC. Safety assessment of Poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, Poloxamer 105 benzoate, and Poloxamer 182 Dibenzoate as used in cosmetics. Int J Toxicol. 2008;27:93–128. https://doi.org/10.1080/10915810802244595.CrossRefPubMedGoogle Scholar
- 21.Huang ZW, Wu H, Yang BB, Chen LK, Huang Y, Quan GL, et al. Anhydrous reverse micelle nanoparticles: new strategy to overcome sedimentation instability of peptide-containing pressurized metered-dose inhalers. Drug Deliv. 2017;24(1):527–38. https://doi.org/10.1080/10717544.2016.1269850.CrossRefPubMedGoogle Scholar
- 22.Helenius A, McCaslin DR, Fries E, Tanford C.  Properties of detergents. Methods in enzymology: Academic Press; 1979. p. 734–49. https://doi.org/10.1016/0076-6879(79)56066-2.
- 27.Huang MJ, Tai C, Zhou QF, Jiang GB. Preparation of polyaniline coating on a stainless-steel wire using electroplating and its application to the determination of six aromatic amines using headspace solid-phase microextraction. J Chromatogr A. 2004;1048(2):257–62. https://doi.org/10.1016/j.chroma.2004.07.059.CrossRefGoogle Scholar
- 30.Bargoni A, Cavalli R, Zara GP, Fundaro A, Caputo O, Gasco MR. Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II - tissue distribution. Pharmacol Res. 2001;43(5):497–502. https://doi.org/10.1006/phrs.2001.0813.CrossRefPubMedGoogle Scholar